Research and development of N,N′-diarylureas as anti-tumor agents

Abstract

Tumor neovascularization provides abundant nutrients for the occurrence and development of tumors, and is also an important factor in tumor invasion and metastasis, which has attracted extensive attention in anti-tumor therapy. Sorafenib is a clinically approved multi-targeted anti-tumor drug that targets vascular endothelial growth factor receptor (VEGFR) and inhibits the formation of tumor angiogenesis, thereby achieving the purpose of suppressing tumor growth. Since the approval of sorafenib, N,N′-diarylureas have received extensive attention as the key pharmacophore in its chemical structure. And a series of N,N′-diarylureas were designed and synthesized to screen a new generation of anti-tumor drug candidates through chemical modification and structural optimization. Moreover, the rational design of targeted drugs is beneficial to reduce toxic side effects and drug resistance and improve the curative effect. Here, this article reviews the research progress in the design, classification, structure–activity relationship (SAR) and biological activity of N,N′-diarylureas, in order to provide some prospective routes for the development of clinically effective anti-tumor drugs.